Academic Journals Database
Disseminating quality controlled scientific knowledge

Dual-Targeting for the Elimination of Cancer Cells with Increased Selectivity

ADD TO MY LIST
 
Author(s): Ingo Schubert | Christoph Stein | Georg H. Fey

Journal: Antibodies
ISSN 2073-4468

Volume: 1;
Issue: 1;
Start page: 2;
Date: 2012;
Original page

Keywords: dual-targeting | cancer therapy | effector cell | triplebody | NK-cell | macrophage | drug conjugates

ABSTRACT
Here we review recombinant proteins with a capability for dual-targeting. These molecules address two different antigens on the same tumor cell and therefore are called “dual-targeting agents”. By virtue of binding a chosen pair of antigens on the malignant cell, preferential binding to antigen double-positive over single-positive cells can be achieved when both are present in the same environment. Therapeutic effects of such agents are based on different modes of action: (1) They can act as pro-apoptotic agents or by inhibiting pro-survival signals; (2) The dual recognition moiety can be fused to effector-domains, such as bacterial toxins or other drugs, leading to the generation of bispecific antibody-drug conjugates (ADCs); (3) Dual-targeting agents can further be used to redirect an effector-cell to the tumor. A new generation of scFv-derived fusion proteins are the tandem single chain triplebodies (sctbs), which carry two scFv binding sites for antigens on the tumor cell plus a third, specific for a trigger molecule on an effector cell. The ability of preferential or selective targeting of antigen double-positive over single-positive cells opens attractive new perspectives for the use of dual-targeting agents in cancer therapy, and possibly also for the treatment of certain inflammatory and autoimmune disorders.
RPA Switzerland

Robotic Process Automation Switzerland

    

Tango Rapperswil
Tango Rapperswil